IMHO a big catalyst will be results of preclinical trials into other neurodegenerative indications.
At the moment we have all our eggs in the ALS basket which carries a fair amount of risk. If it looks like we can bring a second indication into play then that both increases our addressable market and also spreads the risk.
I'd imagine that strong preclinical results in a second indication could easily result in a doubling of the current share price.
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-907
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.46M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35000 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 19363 | 3 |
View Market Depth
| Last trade - 09.24am 03/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable